<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and UAE equivalent to 15-300 mg/24 h, despite <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Compared with placebo, benfotiamine treatment resulted in significant improvement of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> status (P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of <z:chebi fb="4" ids="26948,33283">thiamine</z:chebi> status </plain></SENT>
</text></document>